A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease
Non-erosive Reflux Disease
About this trial
This is an interventional treatment trial for Non-erosive Reflux Disease
Eligibility Criteria
Inclusion Criteria:
- Aged ≥18 years at the time of signing informed consent;
- Have experienced heartburn (burning sensation, pain at posterior bony thorax) for at least 6 months prior to Screening;
- Have documented history of symptomatic GERD;
- Have no mucosal break(s) on the upper GI endoscopy performed during Screening;
- Have reported heartburn on ≥4 days during any consecutive 7-day period of the Screening Period as recorded in the eDiary;
- Able to understand and comply with the protocol requirements;
- Willing and able to provide written informed consent at Screening;
- Is a female of non-childbearing potential, ie, is either surgically sterile (ie, had a hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy ≥6 months before the Screening Visit) or post-menopausal, defined as spontaneous amenorrhea for ≥12 months, and, for females <55 years of age, with follicle-stimulating hormone in the post-menopausal range at Screening, based on the central laboratory's ranges; or If a female of childbearing potential, agrees to use an acceptable form of birth control from the Screening Visit until 30 days after the last dose of study drug.
- If a male, agrees to use an acceptable form of birth control from the Screening Visit until 3 months after the last dose of study drug.
- If a male, agrees to abstain from sperm donation through 3 months after administration of the last dose of study drug.
Exclusion Criteria:
- Unable to undergo an upper GI endoscopy;
Presence of esophageal stricture, gastroesophageal varix (including post sclerotherapy or ligation), untreated Barrett's esophagus, gastric bleeding, infection, tumor, or gastric or duodenal ulcer on the upper GI endoscopy;
o Note: Patients with diagnosis of Schatzki's ring (mucosal tissue ring around lower esophageal sphincter) are eligible to participate.
- Diagnosed with erosive gastroesophageal reflux disease, acute upper GI bleeding, gastric ulcer or duodenal ulcer, or acute gastritis within 2 months prior to the upper GI endoscopy;
- Alarm symptoms such as odynophagia, severe dysphagia, upper GI bleeding, weight loss, anemia, or hematochezia within 4 weeks prior to Screening, unless the presumed malignancy is ruled out;
History or suspicion of functional upper gastrointestinal disorders, such as:
- Functional heartburn, as described in the Rome IV criteria, or
- Functional dyspepsia, as described in the Rome IV criteria.
- History of a connective tissue disorder associated with GI symptoms (eg, scleroderma or systemic lupus erythematous) or inflammatory bowel disease, or documented history of delayed gastric emptying;
History of acid-suppressive, esophageal, or gastric surgery;
o Note: This is not applicable to appendectomy, cholecystectomy, or endoscopic excision of benign tumor.
History of malignancy within the past 5 years (with the exception of resected basal cell or squamous cell carcinoma of the skin);
o Note: This is not applicable to patients who had complete response or pathological complete response and whose tumor had not recurred for at least 5 years from the date of last treatment, or patients whose tumor had been removed by endoscopic resection without any findings indicating recurrence of the tumor within 3 years.
- History of an allergic disease, or hypersensitivity or intolerance to the active ingredient or excipients of the study drug;
History of alcoholism, chronic opiate use, or substance addiction in the 12 months before Screening or a positive urine drug screen for opiates or substances of abuse;
o Note: Patients on prescribed opioids are eligible to participate if they have been on a stable dose for >3 months prior to Screening.
- Presence of manic-depression, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other psychological disorder;
- Current use of antipsychotics, antidepressants, anxiolytics, or prescription sleeping medications, with the exception of a stable dose for >6 months prior to Screening;
- Use of any gastric acid-suppressive agents, including PPIs, within 2 weeks prior to the upper GI endoscopy at Screening;
- Use of 2 or more commercial doses of reflux esophagitis-related medications (including H2 blockers, prostaglandins, mucosal protective agents, prokinetics, and antacids) within 1 week prior to the upper GI endoscopy at Screening;
Requirement of persistent use of non-steroidal anti-inflammatory drugs (NSAIDs) during the course of the study;
o Note: Low-dose (≤100 mg/day) aspirin is allowed provided that it has been used for prophylaxis prior to study participation.
- If a female, is pregnant, breastfeeding, or planning to become pregnant during the study or within 30 days after the last dose of study drug;
- Positive test result for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus at Screening;
Abnormal laboratory results with clinical relevance at Screening as follows:
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase level of ≥2 × upper limit of normal (ULN);
- Total bilirubin level of ≥2 × ULN, unless Gilbert's syndrome is confirmed when direct bilirubin is ≤0.3 mg/dL;
- Estimated glomerular filtration rate <30 mL/min; or
- Serum magnesium <lower limit of normal.
- Abnormal ECG of clinical significance (eg, major arrhythmia, multifocal premature ventricular contractions, or 2° atrioventricular block anomaly);
- Presence of any gastric acid hypersecretory conditions, such as Zollinger-Ellison syndrome;
- Involvement in another clinical study within 4 weeks of initiation of study drug; or
- Any other clinically relevant condition that would confound study endpoints or adversely affect patient compliance with the study procedures in the medical judgment of the Investigator or Medical Monitor based on previous medical history or findings on Screening assessments .
Sites / Locations
- Research Site 24
- Research Site 132
- Research Site 62
- Research Site 27
- Research Site 87
- Research Site 117
- Research Site 51
- Research Site 126
- Research Site 66
- Research Site 19
- Research Site 94
- Research Site 10
- Research Site 55
- Research Site 120
- Research Site 72
- Research Site 54
- Research Site 14
- Research Site 85
- Research Site 13
- Research Site 41
- Research Site 112
- Research Site 89
- Research Site 74
- Research Site 108
- Research Site 91
- Research Site 03
- Research Site 78
- Research Site 09
- Research Site 23
- Research Site 42
- Research Site 38
- Research Site 43
- Research Site 81
- Research Site 67
- Research Site 92
- Research Site 31
- Research Site 71
- Research Site 17
- Research Site 90
- Research Site 107
- Research Site 05
- Research Site 95
- Research Site 11
- Research Site 46
- Research Site 04
- Research Site 59
- Research Site 101
- Research Site 102
- Research Site 01
- Research Site 113
- Research Site 02
- Research Site 135
- Research Site 125
- Research Site 45
- Research Site 12
- Research Site 124
- Research Site 48
- Research Site 34
- Research Site 25
- Research Site 93
- Research Site 111
- Research Site 137
- Research Site 06
- Research Site 73
- Research Site 127
- Research Site 64
- Research Site 129
- Research Site 130
- Research Site 131
- Research Site 35
- Research Site 07
- Research Site 28
- Research Site 58
- Research Site 49
- Research Site 40
- Research Site 75
- Research Site 69
- Research Site 116
- Research Site 20
- Research Site 88
- Research Site 109
- Research Site 118
- Research Site 110
- Research Site 61
- Research Site 128
- Research Site 114
- Research Site 60
- Research Site 103
- Research Site 50
- Research Site 115
- Research Site 100
- Research Site 98
- Research Site 99
- Research Site 68
- Research Site 29
- Research Site 32
- Research Site 30
- Research Site 22
- Research Site 26
- Research Site 21
- Research Site 80
- Research Site 134
- Research Site 121
- Research Site 105
- Research Site 57
- Research Site 106
- Research Site 65
- Research Site 16
- Research Site 77
- Research Site 136
- Research Site 97
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
BLI5100 Low Dose
BLI5100 High Dose
Placebo
During the Treatment Period, patients will take BLI5100 low dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 low dose once daily, orally, for 20 weeks.
During the Treatment Period, patients will take BLI5100 high dose once daily, orally, for 8 weeks. During the Extension Period, patients will continue to take BLI5100 high dose once daily, orally, for 20 weeks.
During the Treatment Period, patients will take placebo once daily, orally, for 8 weeks. In the Extension Phase, patients who received placebo in the Treatment Phase will be re-randomized to receive either BLI5100 low dose or BLI5100 high dose to take once daily, orally, for 20 weeks.